Expert Analysis
Expert Analysis: Insights for International Clinicians on New Data From HIV Glasgow 2020

Released: November 06, 2020

Expiration: November 05, 2021

Marina Klein
Marina Klein, MD, MSc, FRCP(C)
Jean-Michel Molina
Jean-Michel Molina, MD, PhD

Activity

Progress
1
Course Completed

Jean-Michel Molina, MD, PhD:
In this Expert Analysis, Marina Klein, MD, MSc, FRCP(C), and I review new data from the 2020 International Congress on Drug Therapy in HIV Infection (HIV Glasgow) held virtually October 5-8 from Glasgow, United Kingdom. In our discussion, we cover some of the most clinically relevant studies reported, with a focus on how the new findings may affect the practice of clinicians providing care for patients with HIV (PWH) in countries around the world.

Please note that the slide thumbnails in this activity link to a complete PowerPoint slideset that can be found here or downloaded by clicking any of the thumbnails within the activity. 

Clinical Care Options plans to measure the educational impact of this activity, and some questions in this activity will be asked twice, once before the discussion that informs the best choice and again after that specific discussion. Your responses will be aggregated for analysis, but your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many patients with HIV do you provide care for in a typical week?
Results from a pooled Week 144 analysis of the GEMINI-1 and -2 trials demonstrated which of the following outcomes with DTG + 3TC vs DTG + FTC/TDF in treatment-naive patients?
Results from a survey conducted in PWH in Italy revealed which of the following factors associated with awareness of “Undetectable = Untransmittable” (U=U) messaging and the perception of it as highly accurate?
The dose-ranging phase Ib study investigating the first-in-class HIV-1 capsid inhibitor lenacapavir demonstrated which of the following outcomes in patients with HIV by Day 10?